ConductScience.org, home

Paper37814498

A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention.

Leung E and 5 others. CPT Pharmacometrics Syst Pharmacol, 2023. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention. Papers, record 37814498. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37814498

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention.
PubMed
Journal
CPT Pharmacometrics Syst Pharmacol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.16
iCite
Revised in PubMed
2024-05-22
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Leung EErickhttps://orcid.org/0000-0002-3753-1900
2Cottrell MLMackenzie Lhttps://orcid.org/0000-0002-0291-5111
3Sykes CCraig
4White NNicole
5Kashuba ADMAngela D Mhttps://orcid.org/0000-0002-9171-8493
6Dumond JBJulie Bhttps://orcid.org/0000-0002-3500-5819

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
HIV InfectionsMajor topic
Pre-Exposure ProphylaxisMajor topic
Female
Humans
Tenofovir
Emtricitabine

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 AI050410NIAID NIH HHSUnited StatesP30AI050410PubMed and NIHNIH RePORTER
T32 GM086330NIGMS NIH HHSUnited StatesT32GM086330PubMed and NIHNIH RePORTER
5T32GM086330NIGMS NIH HHSUnited StatesT32GM086330PubMed and NIHNIH RePORTER

Download CSV of grants

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125651245Tenofovir-based preexposure prophylaxis for HIV infection among African women.N Engl J Med2015https://conductscience.org/library/papers/25651245PubMed
215217303Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.Clin Pharmacokinet2004https://conductscience.org/library/papers/15217303PubMed
322784040Preexposure prophylaxis for HIV infection among African women.N Engl J Med2012https://conductscience.org/library/papers/22784040PubMed
419104016Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.Antimicrob Agents Chemother2009https://conductscience.org/library/papers/19104016PubMed
522286919A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.AAPS J2012https://conductscience.org/library/papers/22286919PubMed
622972843Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.Sci Transl Med2012https://conductscience.org/library/papers/22972843PubMed
728145472Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.Sci Rep2017https://conductscience.org/library/papers/28145472PubMed
828019088p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.CPT Pharmacometrics Syst Pharmacol2017https://conductscience.org/library/papers/28019088PubMed
921896913Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Antimicrob Agents Chemother2011https://conductscience.org/library/papers/21896913PubMed
1025065857Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.Lancet Infect Dis2014https://conductscience.org/library/papers/25065857PubMed
1124492366Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24492366PubMed
1225390686Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.CPT Pharmacometrics Syst Pharmacol2014https://conductscience.org/library/papers/25390686PubMed
1324203458Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.J Clin Pharmacol2014https://conductscience.org/library/papers/24203458PubMed
1410843462Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.Clin Pharmacokinet2000https://conductscience.org/library/papers/10843462PubMed
1522784038Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.N Engl J Med2012https://conductscience.org/library/papers/22784038PubMed
1626917574A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.J Infect Dis2016https://conductscience.org/library/papers/26917574PubMed
1730150483A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.J Pharmacol Exp Ther2018https://conductscience.org/library/papers/30150483PubMed
1816048948Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/16048948PubMed
1924148552Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects.Clin Ther2013https://conductscience.org/library/papers/24148552PubMed
2031002391Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.Clin Pharmacol Ther2019https://conductscience.org/library/papers/31002391PubMed

See all 31 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42827404Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches.Clin Pharmacol Ther2026https://conductscience.org/library/papers/42827404PubMed
40354181HIV Pharmacology Data Repository: Setting the New Information-Sharing Standard for Clinical and Preclinical Pharmacokinetic Studies.Clin Pharmacol Ther2025https://conductscience.org/library/papers/40354181PubMed
37814498A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention.CPT Pharmacometrics Syst Pharmacol2023https://conductscience.org/library/papers/37814498PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37814498

GET https://conductscience.org/api/papers/v1/37814498/references?page=2